ROCHESTER, Minnesota, Oct. 11, 2024 – Cytotheryx, Inc., a privately held company focused on the development of a consistent, high-quality source of human hepatocytes (liver cells) for cell-based therapies to address acute, chronic and rare forms of liver disease, announced today that John Swart, PhD, Chief Executive Officer, will participate in the UBS Virtual Organ Restoration and Cell Therapy Day, taking place on October 15, 2024.

Fireside Chat with Ash Verma, SMID-cap Biotech & Specialty Pharma Analyst, UBS Equity Research
Date: Tuesday, October 15, 2024
Time: 2:00 p.m. – 2:45 p.m. ET

To register for the event, please contact your UBS representative.

Serious liver diseases affect almost 5 million people in the US, with limited treatment options. Cell-based therapies may provide the best opportunity to treat liver disease, but until recently, sufficient quantities of mature liver cells have not been available. Cytotheryx has developed a proprietary bio-incubator that has the potential to produce high-quality liver cells at a scale that can address this significant need.  

About Cytotheryx, Inc.
Cytotheryx, Inc. is a pre-clinical biotechnology company utilizing a proprietary technology developed by the Mayo Clinic to address liver failure. The lead program at Cytotheryx addresses the supply shortage of primary human hepatocytes, the gold standard for in vitro modeling of the liver in drug toxicity and metabolic studies, as well as in liver disease-specific research. Learn more at https://www.cytotheryx.com and follow us on LinkedIn.

Investor and Media Contact:
Anna Argo
Chief Business Officer
Mobile: +1 (612) 834 2649
Tel: +1 (877) 275 2986
Email: anna.argo@cytotheryx.com